Premium
Tyrosine Kinase Inhibitors and Male Reproductive Health
Author(s) -
Ramstein Joris J.,
Tsai Katy K.,
Smith James F.
Publication year - 2017
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.813
Subject(s) - tyrosine kinase , harm , medicine , mechanism of action , mechanism (biology) , biology , pharmacology , cancer research , genetics , psychology , receptor , social psychology , philosophy , epistemology , in vitro
Tyrosine kinase inhibitors (TKIs) are a targeted class of cancer therapies effective against a range of malignancies and their use is growing significantly each year. Many men taking TKIs desire children, yet very little is known about the potential for reproductive harm of these medications. The mechanism of action of TKIs suggest a possible route to impairment of sperm functional properties or spermatogenesis.